ituitary tumors are the underlying pathological entity in approximately 99% of cases of acromegaly and are nearly always benign. These lesions chronically produce supraphysiological levels of GH and IGF-I. 39 Elevated GH and IGF-I levels are considered to be responsible for a wide range of cardiovascular, respiratory, endocrine, and metabolic morbidities. 19, 45 In a metaanalysis of 16 previously published studies surveying the mortality effects of acromegaly, Dekkers et al. 23 found an overall 72% increase in deaths in patients with acromegaly compared with the general population.
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Acromegaly is a relatively rare disorder; the incidence is roughly 4 new cases per million annually. 4 Clinically, acromegaly is characterized by slowly progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations. Ultimately, the rheumatological, cardiovascular, respiratory, and metabolic consequences determine prognosis. 11 However, given the typical indolent presentation of the disease, the diagnosis of acromegaly is often delayed. The authors of many older series have reported a delay in the diagnosis of 7-10 years after the onset of signs and symptoms. 24 However, in a recent retrospective study Nachtigall et al. 50 reported a decrease in this interval to roughly 2-3 years. Given that tumor size has been established as an important predictor of surgical outcome, early recognition and treatment are considered keys to achieving high rates of remission and avoiding long-term comorbidities. 16, 49 Total surgical removal of GH-secreting tumors offers the possibility of hormonal control of acromegaly as well as amelioration in the associated multisystem morbidities. 48 As such, recent consensus guidelines recomOutcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas mend surgery for the management of acromegaly as the first-line therapy in cases involving tumors likely to be controlled by surgery. 25, 46, 48 Thus, in patients with acromegaly, the goals of surgical treatment are to normalize biochemical markers, eliminate morbidities associated with the disease, relieve mass effect, and subsequently normalize the overall mortality rate. 46, 63 While the microsurgical transsphenoidal route has historically been the favored approach to these lesions, the addition of the endoscope to this procedure represents a recent innovation, allowing the surgeon a panoramic view irrespective of the width and depth of the access. 22, 52 We report our experience with the resection of each consecutive GHsecreting pituitary adenoma presenting over a 50-month period; all tumors were excised via an entirely endoscopic trans sphenoidal approach.
Methods

Patient Population
After obtaining the approval of the Thomas Jefferson University institutional review board, we performed a retrospective review of a prospectively maintained database and evaluated the medical records of 27 consecutive patients who presented with GH-secreting adenomas from June 2005 to September 2009. One patient relocated abroad postoperatively and was subsequently lost to follow-up. This patient underwent microadenoma resection, was discharged on postoperative Day 2, and had an initial unremarkable postoperative visit; however, laboratory evaluations and longer-term results were not available. Of the remaining 26 patients, ages ranged from 20 to 69 years (mean 45.7 years) ( Table 1 ). There were 14 men and 12 women, all of whom presented with clinical signs of acromegaly. Hypertension was the most common associated symptom (42.3%), with obstructive sleep apnea, headache, and arthralgias being reported in 38.5% of patients (Table 1) . If decreased acuity or visual fields were noted on the initial screening examination, patients were referred for formal ophthalmological evaluation before and after surgery. The follow-up duration ranged from 3 to 60 months (mean 24.5 months).
Endocrine Evaluation
All patients underwent full preoperative endocrine laboratory evaluations, which were repeated at 3, 6, and 12 months postoperatively and annually thereafter. Criteria for endocrine remission were adopted from the literature as follows: normal age-and sex-matched IGF-I concentration and a nadir GH level during oral glucose load of less than 1.0 μg/l and a random GH value of less than 2.5 μg/l. 55 We considered early remission to have been achieved if these parameters were met. The results of the additional followup visits were reviewed to evaluate recurrence.
Imaging Evaluation and Tumor Classification
All patients underwent thin-cut preoperative CT and MR imaging (MR imaging). Postoperative MR imaging was performed within 24 hours of surgery and repeated at 3 and 12 months to confirm the extent of tumor removal. All pituitary adenomas were classified by size and extension on postcontrast MR imaging. Tumors less than 1 cm were classified as microadenomas, while those greater than or equal to 1 cm were recorded as macroadenomas ( Table 2 ). Volumetric analysis of the tumor was calculated using the diameter method. 61 Parasellar extension was recorded using both Hardy classification and Knosp scoring.
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Treatment Protocol
All patients were treated using identical surgical procedures. All operations were performed or supervised by the senior neurosurgeons (J.J.E. and D.W.A.) using a purely endoscopic endonasal approach, which has been described in detail elsewhere in the literature. 6, 22, 43, 56 No transcranial procedures were performed in this series. Patients in whom sufficient biochemical relief was not achieved postoperatively received adjuvant treatment on the basis of residual tumor burden, endocrine studies, available medical and radiosurgical treatment options, and patient preference.
Statistical Analysis
Data analysis was performed using SPSS 8.0 software (SAS Institute). The differences in outcome in relation to tumor volume, biochemical cure, extent of invasion, extent of resection, and preoperative GH levels were investigated by calculating Fisher exact or chi-square tests. A probability value of less than 0.05 was considered statistically significant. 
Results
Surgical Results
The overall rate of endocrinological remission in the group of 26 patients who underwent endoscopic transsphenoidal surgery was 57.7% (that is, remission in 15 of 26 patients). The surgical outcomes are reported in Table  2 . A gross-total resection was accomplished in 19 patients (73.1%). Five patients (19.2%) presented after having 1 or 2 previous microscopic transsphenoidal resections by other surgeons. Of these 5 patients, 2 met the criteria for cure postoperatively. Postoperative radiosurgery was performed in 2 patients (7.7%) with residual tumor in the cavernous sinus. Ultimately, both of these patients required continued medical therapy. Medical therapy (primarily octreotide) was administered in 9 patients (34.6%) in whom a biochemical cure was not achieved by surgery or radiosurgery. One patient was concomitantly treated with octreotide and bromocriptine.
Seven patients (26.9%) presented with visual field defects as demonstrated by formal perimetry and visual field testing. While 5 patients noted an improvement postoperatively, 2 did not. No patient experienced a decrease in visual field or acuity postoperatively. The LOS ranged from 2 to 7 days (mean 2.8 days). Nearing the conclusion of the study period, patients were routinely discharged on the 2nd postoperative day.
Remission Rate by Size and Invasion
Clinical follow-up ranged from 3 to 60 months (mean 24.5 months). The best endocrinological results were achieved in patients with microadenomas; in 3 (75%) of 4 these patients, a biochemical cure was achieved. For those with macroadenomas, a postoperative remission was noted in 54.5% (Table 2 ). Tumor volume, as calculated by the diameter method, ranged from 0.3 to 57.37 cm 3 (mean 14.11 cm 3 ) ( Table 3 ). In patients with larger tumor volumes, a biochemical cure or a gross-total resection was significantly less likely (p = 0.0076 and p < 0.0001, respectively). Parasellar extension was grouped into Grades 0-4 based on Knosp and Hardy classification systems.
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The mean Knosp score was 1.8 and mean Hardy classification was 2.4. Patients with Knosp or Hardy Grade 3 or 4 were less likely to experience a cure (p = 0.0068 and p = 0.013, respectively). Table 4 provides a summary of the results of univariate analysis of factors associated with the lack of postoperative remission. 
Surgical Complications
There were no major complications, but minor complications occurred in 3 patients (11.5%). Transient postoperative diabetes insipidus was observed in 2 patients and was treated medically with desmopressin. One patient required 3 doses, and the other required treatment with a nightly dose for 1 month prior to resolution. A postoperative CSF leak occurred in 1 patient after resection of a macroadenoma with a high-flow cranial base defect. This CSF leak resolved after insertion of a lumbar drain, no morbidity occurred. No deaths or cases of meningitis were observed.
Discussion
Therapy for acromegaly is directed at the control of tumor growth, restricting GH hypersecretion, and normalizing IGF-I levels and the long-term objective is to reduce the morbidity and mortality rate to a level comparable to that of the general population. 48 To objectively measure postoperative GH function, typically after an OGTT, IGF-I is measured to assess the biochemical response to treatment. However, there has been considerable debate as to the accepted criteria to define biochemical remission. 2, 28, 41, 60 In the past, random GH levels less than 5 μg/l and/or an OGTT suppression of GH less than 2 μg/l were acceptable thresholds for the remission of the disease. 1, 41 In 2000, the Acromegaly Treatment Workshop presented international consensus criteria that defined biochemical control as a normal IGF-I for age and sex as well as a GH less than 1.0 μg/l during an OGTT. 30, 47 However, the validity of this boundary was questioned in 2005 by a consensus workshop that determined that GH nadir values should more closely approximate those of healthy individuals, and thus GH after OGTT should fall below 0.4 μg/l. 46 Ronchi et al. 55 reevaluated 70 patients meeting international consensus criteria for control and reported no significant difference in clinical, biochemical, and hormonal parameters in patients in whom GH was suppressed after OGTT at 0.4 μg/l or 1.0 μg/l upon long-term follow-up. While many postoperative patients will be considered "cured" by the current criteria, OGTT GH nadir often remains higher than what is observed in healthy controls, the significance of which remains uncertain. Several authors have suggested that a purely endoscopic approach to sellar pathology offers improved visualization, preservation of sinonasal function and superior patient comfort while decreasing hospital LOS compared with traditional microscopic transsphenoidal techniques. 8, 33, 51 Furthermore, many posit the use of angled endoscopes provides a field of view that is significantly larger and may enhance the identification of critical neurovascular structures, allow for a better assessment of the extent of the resection, and subsequently decrease the complication rate. 59, 62 The authors of several series have retrospectively contrasted their results after using a purely endoscopic approach with the current "gold standard" traditional microscopic approaches.
9,12,21,22,27,65 Although we are not aware of any randomized studies, a few studies present retrospective outcome data after microscopic and endoscopic approaches before and after the investigators adopted the endoscope into routine practice. For secretory adenomas Cho and Liau 12 reported a control rate of hormonal hypersecretion of 73% after microscopic surgery, but the cure rate was 64% and the complication rate was significantly lower after these authors transitioned their practice patterns to using the endoscopic procedure. Conversely, D'Haens et al. 21 reported an increased cure rate (to 65% from 50%) with endoscopic removal of secretory adenomas, with a slightly higher rate of CSF leakage. While endoscopic approaches provide many theoretical benefits over standard microscopic techniques, recent publications have not consistently shown improvement in resection and complication rates in the endoscopic group. 58 However, high-volume endoscopic studies with long-term follow-up data (similar to those available in the microscopic literature) will ultimately be required to draw relevant conclusions.
Purely endoscopic approaches to pituitary adenomas have been described as a safe and effective alternative to the traditional microscopic procedure. 21, 22, 27, 31 The authors of series dedicated to outcomes after the microsurgical treatment of GH-secreting adenomas have described biochemical cure rates after microscopic procedures ranging from 42% to 67%, using the most recent criteria. 3, 29, 36, 40, 42, 52, 63 To assess biochemical cure rates after a purely endoscopic resection, the results typically must be separated from endoscopic series reporting data on all adenomas ( Table  5) . In these series, cure rates range from 57% to 100%. 7, 10, 13, 21, 22, 27, 31, 33, 34, 44, 57, 66 We are aware of only one early study that focused specifically on outcomes after endoscopic resection in the setting of acromegaly. 44 In this early study the authors reviewed the cases of 5 patients with mostly microadenomas and reported a cure rate of 100% using a liberal cure benchmark. In comparing the results of the traditional series with endoscopic counterparts, bias may be introduced by the use of a short follow-up period, as GH-secreting adenomas in a previously assumed cured patient may recur after many years of follow-up. 15, 38, 52 In these lumped endoscopic series, precise reporting of tumor volume, frequency of follow-up, use of adjuvant medical therapy, and stereotactic radiosurgery for those in the acromegaly subset are often not defined, making comparison across studies difficult. Additionally, the number of patients with suprasellar and cavernous sinus invasion also varies when reported. The results of the present series are slightly less robust compared with the previously reported endoscopic series. However, the baseline patient characteristics in this study included 84.6% macroadenomas, 19.2% revisions, and an overall mean Knosp grade of 2.4, which represents more invasive disease at presentation than in most other series. Overall, the complication rates have typically been commensurate between endoscopic and microsurgical techniques. 22, 53 In a study of two groups of 25 patients undergoing microscopic approaches and endoscopic approaches, O'Malley et al. 53 described similar complication rates between the groups for both CSF leak and incidence of diabetes insipidus, with a trend toward less diabetes insipidus in the endoscopic group. Overall complications realized in this cohort of patients were 11.5% with no major complication requiring return to the operating room, permanent deficit, or treatment. Transient diabetes insipidus occurred in 2 patients (7.7%), while no permanent diabetes insipidus was noted. This result is significantly lower than the 7.6% rate of persistent diabetes insipidus in the historical microscopic cohort.
14 One patient (3.8%) experienced a postoperative CSF leak, which resolved after 3 days of lumbar cistern drainage. This result is similar to others in the literature; Dehdashti et al. 22 reported a rate of 3.5% as compared with the 3.9% historical average in large microscopic series. In this series, no patient experienced a worsening of visual fields or acuity, while 5 patients noted an improvement.
Invasion of the cavernous sinus occurs in roughly 6%-10% of pituitary adenomas and is an arduous challenge in the management of these tumors. 26, 37, 64 In this situation, Couldwell 20 noted that microscopic transsphenoidal exposures are profoundly limited because of the narrow midline corridor around the sella. However, endoscopic techniques may allow for a more accommodating approach to the medial and inferior walls of the cavernous sinus and thus may increase the rates of total excision in this scenario. 10 In the current series, we noted significant difficulty in resolving hormonal hypersecretion in patients with extensive cavernous sinus and parasellar invasion despite the endoscopic access. Complete resection and hormonal resolution occurred in few patients in this category (Fig. 1) . Overall, surgery in patients with Knosp Grade 3 or 4 adenomas was significantly less likely to achieve a biochemical cure (p = 0.0068). Management of pituitary lesions with extrasellar extension is a source of ongoing controversy. A significant proportion of patients with large macroadenomas extending outside the sella will experience persistently elevated GH levels postoperatively, often requiring subsequent medical therapy and/or radiosurgery to gain satisfactory biochemical control. 5, 18 Some authors have argued primary medical therapy may be used for patients with GH-secreting macroadenomas with extrasellar extension, which makes complete surgical resection unfeasible. 5, 18 However, other authors have asserted that initial operative debulking of these macroadenomas may increase the proportion of patients that subsequently attain hormonal control with adjunctive therapy, particularly if more than 75% of the initial tumor volume is resected. 17, 35, 48, 54 To demonstrate safety and efficacy an attempt was made to carefully evaluate and report the biochemical results of endoscopic resection of GH-secreting adenomas in the current series. However, there are several important limitations of this study. This is a retrospective single-institution study with no direct comparison between the traditional microscopic and endoscopic groups. The mean follow-up period was 24.5 months and no cases of biochemical relapse were noted. In microscopic surgical series, long-term follow-up has consistently identified relapse rates ranging from 0.6% to 10%. 15, 38, 52 It remains unresolved and untested as to whether the endoscopic technique can result in a similar or lower incidence of delayed recurrence. 22 We evaluated 26 consecutive patients presenting over a 50-month period. It is unclear if the demographics of this patient population (the relatively high number of revision cases [19.2%] , tumor volume, and extent of parasellar extension) are comparable to other reported series with regard to outcome after endoscopic resections (Table 5 ). 
Conclusions
To the best of our knowledge, this is the first study aimed solely at reporting the outcomes after an endoscopic endonasal resection of GH-secreting adenomas. The results authenticate the efficacy and safety of endoscopic pituitary surgery in the setting of acromegaly. While long-term results are needed to ultimately define tumor control, a favorable comparison with historical results supports the continued use of endoscopic techniques. We believe the advantages of endoscopic approaches, including minimal postoperative discomfort, the associated development of expanded approaches, the relative ease of reoperation if necessary, and superior visualization provided by 3D and angled endoscopes, will ultimately position this technique as the favored approach for the future treatment of pituitary adenomas. 
